Wu Deen
11 Papers
Wu Deen is an academic researcher. The author has contributed to research in topics: Blinatumomab & Medicine. The author has an hindex of 2, co-authored 8 publications.
Chat about Author
Papers
A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Nicholas J. Short,Hagop M. Kantarjian,Marina Konopleva,Guillermo Montalban-Bravo,Farhad Ravandi,Nitin Jain,Tapan M. Kadia,Yesid Alvarado-Valero,Kelly S. Chien,Naval Daver,W. Macaron,Koji Sasaki,Jennifer Thankachan,Ricardo Delumpa,E. Mayor,Wu Deen,Christopher R. Loiselle,Monica Kwari,Rebecca Garris,Elias Jabbour +19 more
TL;DR: The chemotherapy-free combination of ponatinib and blinatumomab was safe and effective in Ph+ ALL and CML-LBP and longer follow-up continues to demonstrate durable remissions, particularly in ND Ph- ALL, even without SCT in first remission.
7
Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial
F. Haddad,Elias Jabbour,Nicholas J. Short,Nitin Jain,Xuelin Huang,Guillermo Montalban-Bravo,Tapan M. Kadia,Naval Daver,C. Nasnas,E. Mayor,Patrice Nasnas,Wu Deen,Maria das Graças Bichara Zoghbi,Jennifer Thankachan,Christopher R. Loiselle,Rebecca Garris,Farhad Ravandi,Hagop M. Kantarjian +17 more
TL;DR: The chemotherapy-free combination of blinatumomab and ponatinib is safe and effective in newly diagnosed Ph-positive ALL, with high rates of MRD negativity.
6
Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
Nicholas J. Short,Hagop M. Kantarjian,Nitin Jain,Xuelin Huang,Guillermo Montalban-Bravo,Tapan M. Kadia,Naval Daver,Kelly S. Chien,Yesid Alvarado,Guillermo Garcia-Manero,Ghayas C Issa,W. Macaron,F. Haddad,Monica Kwari,Ricardo Delumpa,E. Mayor,Wu Deen,Jennifer Thankachan,Christopher R. Loiselle,J. Rivera,Anna Milton,Lourdes Waller,Glenda Banks,Rebecca Garris,Marina Konopleva,Farhad Ravandi,Elias Jabbour +26 more
TL;DR: Ponatinib and blinatumomab both have single-agent activity in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and may reduce the need for allogeneic stem cell transplantation (SCT) in first remission as discussed by the authors .
4
A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Nicholas J. Short,Elias Jabbour,Nitin Jain,W. Macaron,Xuelin Huang,Guillermo Montalban-Bravo,Tapan M. Kadia,Naval Daver,F. Haddad,M. Zoghbi,Lewis Nasr,E. Mayor,Wu Deen,Jennifer Thankachan,Christopher R. Loiselle,Rebecca Garris,Marina Konopleva,Farhad Ravandi,Hagop M. Kantarjian +18 more
TL;DR: Ponatinib and blinatumomab are both active in Ph+ ALL and a combination of these agents may lead to durable remissions when given in the frontline setting and may eliminate the need for chemotherapy or stem cell transplant (SCT) as discussed by the authors .
4
A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Daniel Nguyen,Elias Jabbour,Nicholas J. Short,Ghayas C Issa,Musa Yilmaz,Naval Daver,Naveen Pemmaraju,Kelly S. Chien,Lucia Masarova,Farhad Ravandi,Nitin Jain,Wu Deen,Ming Zhao,Christopher R. Loiselle,Lourdes Waller,Glenda Banks,Rebecca Garris,Hagop M. Kantarjian +17 more
TL;DR: In this paper , a phase II study, adults with either newly diagnosed (ND) acute lymphoblastic leukemia (ALL), relapsed/refractory (R/R) Ph+ ALL, or chronic myeloid leukemia in lymphoid blast phase (CML-LBP) were eligible.
2